Skip to main content
OpenTrials

Clinical trial condition

Hematologic Diseases

Explore clinical trials studying Hematologic Diseases. Study availability and eligibility vary by location and protocol.

15,467 public trials 2,848 recruiting studies
Refine in advanced search Browse all conditions

Hematologic Diseases trial results

Active, not recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma

NCT05646836

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Royal Adelaide Hospital Adelaide, South Australia, Australia
  • Peter Maccallum Cancer Centre Melbourne, Victoria, Australia
  • Alfred Hospital Melbourne, Victoria, Australia
  • Sygehus Lillebaelt - Vejle Sygehus Vejle, Denmark
View all 13 locations
View Trial Details
Active, not recruiting

First-in-Human Study of ICT01 in Patients With Advanced Cancer

NCT04243499

Conditions
Hematologic Diseases, Hematologic Neoplasms, Hematopoietic/Lymphoid Cancer, +4 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Yale Cancer Center New Haven, Connecticut, United States
  • H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States
View all 29 locations
View Trial Details
Active, not recruiting

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

NCT05831111

Conditions
DNA Virus Infections, Epstein-Barr Virus Infection, Epstein-Barr Virus Infections, +12 more
Locations
  • Pinnacle Research Group, LLC Anniston, Alabama, United States
  • Noble Clinical Research Tucson, Arizona, United States
  • Marvel Clinical Research Huntington Beach, California, United States
  • Tekton Research Longmont, Colorado, United States
View all 34 locations
View Trial Details
Active, not recruiting

Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS

NCT05457010

Conditions
Acute Myeloid Leukemia, Bone Marrow Diseases, Hematologic Diseases, +7 more
Locations
  • City of Hope Duarte, California, United States
  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Montefiore Einstein Cancer Center New Rochelle, New York, United States
View Trial Details
Active, not recruiting

IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

NCT03744390

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
Locations
  • Hôpital André Mignot Versailles, LE Chesnay, France
  • CHU Montpellier St Eloi Montpellier, France
  • CH d'Angers/Service des Maladies du sang Angers, France
  • centre hospitalier Victor Dupouy Argenteuil, France
View all 22 locations
View Trial Details
Active, not recruiting

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

NCT05936359

Conditions
Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, +8 more
Locations
  • Royal Brisbane and Women'S Hospital Herston, Queensland, Australia
  • Royal Adelaide Hospital Adelaide, South Australia, Australia
  • Peter Maccallum Cancer Centre Melbourne, Victoria, Australia
  • The Alfred Hospital Melbourne, Victoria, Australia
View all 28 locations
View Trial Details
Active, not recruiting

IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

NCT03503409

Conditions
Acute Myeloid Leukemia, Bone Marrow Diseases, Hematologic Diseases, +7 more
Locations
  • CH Angers Angers, France
  • Centre Hospitalier de la Côte Basque Bayonne, France
  • Hôpital Nord Franche-Comté/Service de médecine interne / Hématologie clinique Belfort, France
  • CHU côte de Nacre Caen, France
View all 38 locations
View Trial Details

Related conditions